The apex court on Monday ruled that the compound for which Novartis was seeking a patent "did not satisfy the test of novelty or inventiveness" required by Indian law.
After the landmark ruling, activists say it will protect access to cheap generic versions of drugs in developing nations.
Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster cancer drug Glivec, arguing that the compound was a significant improvement because it is more easily absorbed by the body.
API Active Pharma Ingredients are the substances which goes inside the body and fights against the diseases. But to make it easily soluble in body there are various formats which is created by the pharma companies and these are typically patented in US EU and Japan, but SC in India said that unless it is advanced than its earlier form and give a substantiate benefit it can not be called as significant improvement and patent can not be done and hence its rejecting Novartis's claim.
This is a landmark ruling which will pave way the path for drug companies in developing economics to produce generic versions of lifesaving drugs and a major jolt to the big MNCs plan to reap benefit from the disease prone big population in these countries..
After the landmark ruling, activists say it will protect access to cheap generic versions of drugs in developing nations.
Novartis fought a seven-year legal battle to gain patent protection for an updated version of its blockbuster cancer drug Glivec, arguing that the compound was a significant improvement because it is more easily absorbed by the body.
API Active Pharma Ingredients are the substances which goes inside the body and fights against the diseases. But to make it easily soluble in body there are various formats which is created by the pharma companies and these are typically patented in US EU and Japan, but SC in India said that unless it is advanced than its earlier form and give a substantiate benefit it can not be called as significant improvement and patent can not be done and hence its rejecting Novartis's claim.
This is a landmark ruling which will pave way the path for drug companies in developing economics to produce generic versions of lifesaving drugs and a major jolt to the big MNCs plan to reap benefit from the disease prone big population in these countries..
No comments:
Post a Comment